DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.

@article{Foss2000DAB389IL2A,
  title={DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.},
  author={Francine Mary Foss},
  journal={Clinical lymphoma},
  year={2000},
  volume={1 2},
  pages={110-6; discussion 117}
}
Fusion proteins are recombinant molecules that combine a targeting mechanism to a cytocidal moiety. DAB(389)IL-2 (denileukin diftitox; ONTAK), with a unique mechanism of action, is the first genetically constructed fusion protein to reach the clinic. In this molecule, the interleukin-2 (IL-2) gene is genetically fused to the enzymatically active and translocating domains of diphtheria toxin. DAB(389)IL-2 is internalized into IL-2 receptor-bearing cells by endocytosis. The ADP-ribosyltransferase… CONTINUE READING
39 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

Similar Papers

Loading similar papers…